Lv1
22 积分 2023-03-09 加入
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
1小时前
求助中
Department of Error
3天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
10天前
已完结
Emerging evidence for adapting radiotherapy to immunotherapy
1个月前
已完结
Anti–Epstein–Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer
2个月前
已完结
Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma
2个月前
已完结
Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era
2个月前
已完结
Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
2个月前
已完结
Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension
2个月前
已完结
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas
3个月前
已完结
皖公网安备34019202002308
